Emerging antimicrobial resistance and need for antimicrobial stewardship for ocular infections in India: A narrative review

Partha Biswas¹, Sneha Batra¹,², Neha Gurha³, Nitin Maksane³

Patients with ocular infections are at increased risk of vision impairment and may require immediate medical care to preserve their vision. Management of ocular bacterial infections has evolved in recent years and includes a pragmatic selection of broad-spectrum antibiotics based on the causative bacteria. Nevertheless, the treatment of bacterial ocular infections is increasingly becoming a challenge, as the causative bacterium acquires resistance to antibiotics through intrinsic and acquired methods. From an Indian perspective, along with the challenges of antibiotic resistance, there are other factors such as lack of knowledge on epidemiology, and lack of data on local susceptibility patterns of ocular pathogens that have significant impact on the management of ocular infections. This narrative review summarizes the available knowledge on prescribing antibiotics for five common ocular infections in India. It further highlights the significance of the understanding of antimicrobial susceptibility patterns across India as a cornerstone to promote rational use of ocular antibiotics. This review indicates that large-scale antimicrobial resistance surveillance studies can facilitate the synchronization of ophthalmic antimicrobial prescription policies with local antibiotic resistance patterns. Further, establishment of an antimicrobial stewardship program in ophthalmology can potentially increase the efficacy of diagnostic tools, and implement earlier adoption of effective antibiotics. Overall, this review provides consolidated information and key considerations for treatment decision-making of common ocular infections in India.

Key words: Antimicrobial stewardship, blepharitis, dacryocystitis, India, ocular infections

Common microbial ocular infections include conjunctivitis, keratitis, endophthalmitis, uveitis, blepharitis, orbital cellulitis and dacryocystitis. The diagnosis of these ocular infections is challenging due to diverse presentations; moreover, lack of prompt intervention may result in long-term vision impairment. Ocular infections are caused by a diverse group of microorganisms such as bacteria, fungi, parasites, and viruses. Bacterial ocular infections are caused by both gram-positive and gram-negative bacteria; however, gram-positive bacteria are predominant. The most prevalent causative bacterial pathogens include Staphylococcus aureus (S. aureus), coagulase negative Staphylococci, Streptococcus pneumoniae (S. pneumoniae) and Pseudomonas aeruginosa (P. aeruginosa). The management of ocular infections is empiric and usually involves the use of broad-spectrum antibiotics in the form of eye drops, ointments, and intra-ocular formulations. The widespread and indiscriminate use of conventional antibiotics in ocular infections, together with improper dosing regimen, polypharmacy, and the absence of global ocular antibiotic prescription guidelines have resulted in antimicrobial resistance (AMR) among gram-positive and gram-negative bacteria.

AMR among ocular pathogens has emerged as a public health concern in the past decade. S. aureus, one of the most prevalent ocular pathogens, has developed resistance to methicillin, producing an ocular methicillin-resistant S. aureus (MRSA) strain, which is the principal causative agent in vision-threatening infections. Furthermore, the management of MRSA infections is challenging due to the multidrug resistance accrued by these pathogens. Similar to MRSA, other ocular pathogens such as P. aeruginosa isolates have also developed resistance to broad-spectrum antibiotics. AMR has a significant impact on the national healthcare system as well as the economy. An economic analysis study conducted by the World Bank in 2017 estimated that by the year 2050, the annual global GDP impact of AMR may range from 1.1% to 3.8%, while the increase in overall global healthcare costs may range from 300 billion USD to more than 1 trillion USD annually.

Studies estimate that by the year 2050, Asia may experience up to 4.7 million deaths directly attributed to AMR (https://rr-asia.oie.int/wp-content/uploads/2020/03/thailand_thailands-national-strategic-plan-on-amr-2017-2021.pdf). Antimicrobial resistance is attaining significance in India, with up to 12–59% of E. coli being extended-spectrum beta-lactamase (ESBL) producers, and up to 30% being carbapenemase producers (CP).

This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.

For reprints contact: WKHLRPMedknow_reprints@wolterskluwer.com

Cite this article as: Biswas P, Batra S, Gurha N, Maksane N. Emerging antimicrobial resistance and need for antimicrobial stewardship for ocular infections in India: A narrative review. Indian J Ophthalmol 2022;70:1513-21.
**Common Bacterial Ocular Infections: Diagnosis and Management**

Bacterial infections are the most common ocular infections and can range in severity from self-limiting bacterial conjunctivitis to potentially sight-threatening conditions such as endophthalmitis. Thorough assessment of distinctive clinical symptoms is essential to determine the ocular involvement and provide accurate diagnosis. The intra-ocular infections may occur subsequent to a corneal ulcer, penetrating eye injury, or a severe bloodstream infection, and presents as iritis, uveitis, chorioretinitis, or endophthalmitis. Common ocular infections in India such as blepharitis, conjunctivitis, dacryocystitis, keratitis and endophthalmitis are discussed in detail below, and treatment recommendation is summarized in Table 1.

All the management guidelines mentioned in this paper have been quoted from the National Treatment Guideline for Antimicrobial Use in Infectious Diseases published in the year 2016 by the National Centre for Disease Control, DGHS, MoHFW, Govt. Unfortunately, since then there have been no comprehensive guidelines published to guide ophthalmologists regarding updated judicious use of antimicrobials in eye infections. The Treatment Guidelines for Antimicrobial Use in Common Syndromes published by the ICMR in 2019 which provided updated guidelines for judicious antimicrobials omitted eye infections altogether.

**Blepharitis**

Blepharitis is a chronic ophthalmic disease characterized by inflammation of the eyelids. Although the exact pathogenesis of blepharitis is unknown, the etiology of blepharitis is attributed to staphylococcal bacteria (S. aureus, S. epidermidis, methicillin-susceptible S. aureus (MSSA) or MRSA), eye inflammation, or tarsal gland abnormalities. Common symptoms associated with bacterial blepharitis include irritation of the eyelids, tearing, eyelash loss, eyelid ulceration, eyelid scarring, itching, tear film instability, and red eyes.

Primary clinical management of blepharitis involves maintaining ocular and hand hygiene. Warm wet compresses to the eye are suggested to soften eyelid debris and dilate meibomian glands followed by gentle wash. The National Centre for Disease Control guidelines (NCDC) in India recommends the use of oral claxoxicillin and oral cephalaxin for blepharitis caused due to MSSA/S. epidermidis, and oral trimethoprim when the causative pathogen is MRSA. Topical antibiotics like bacitracin or erythromycin that are applied to the lid margins are used for the management of acute blepharitis. Topical agents like fusidic acid, metronidazole, and fluoroquinolones have also proven their efficacy in encouraging antibiotic prescription based on local resistance patterns. Therefore, an improved understanding of the patterns of antibiotic use and AMR in India is crucial for effective implementation of AMS programs.

The objective of this narrative review is to consolidate current knowledge on the management of common ocular infections, and promote rational use of ocular antibiotics in India. This narrative review is aimed to provide useful insights to the ophthalmologists in treatment decision-making and optimal selection of antibiotics for ocular infections.
| Ocular Infection | Causative Pathogen | Pharmacological Treatment | Surgical Treatment | Supportive Care | Source |
|------------------|--------------------|---------------------------|--------------------|----------------|--------|
| Blepharitis      | MSSA/S. epidermis   | Oral Cloxacillin 250-500 mg qid or Oral Cephalexin 500 mg qid | lid margin care with baby shampoo and warm compresses 24 hourly. Artificial tears, if associated with dry eye. Thermal pulsation and intense pulsed light therapy for posterior blepharitis. | Lid margin care with baby shampoo and warm compresses 24 hourly. Artificial tears, if associated with dry eye. Thermal pulsation and intense pulsed light therapy for posterior blepharitis. | NCDC Guidelines[^2] |
|                  | MRSA               | Oral Trimethoprim sulphonamethoxazole 960 mg BD or Linezolid 600 mg BD | | | |
| Conjunctivitis (Bacterial) | S. aureus, S.pneumoniae, Haemophilus influenzae, Neisseria gonorrhoeae or, Chlamydia trachomatis | Ophthalmologic solution: Moxifloxacin 0.5% 1-2 drops q2h while awake during first 2 days, then q4-8h upto 7 days, Gatifloxacin 0.3%, levofloxacin 0.5% | Maintaining ocular and hand hygiene. Antibiotics to be avoided for self-limiting viral conjunctivitis. | | NCDC Guidelines[^2] |
|                  |                    | Topical antibiotics: Broad-spectrum antibiotics - fluoroquinolones, aminoglycoside antibiotic (gentamicin),[^33] Oral antibiotics: Fluoroquinolones, amoxicillin-clavulanic acid, and third generation cephalosporins. Intravenous antibiotics: Combination of penicillin antibiotic and beta-lactam antibiotic,[^33] ceftriaxone, and fluoroquinolones. | | | NCDC Guidelines[^2] |
| Keratitis (Bacterial) | S. aureus, S.pneumoniae, S.pyogenes, Haemophilus and Pseudomonas species | First-line agent: Moxifloxacin topical (0.5%): 1 drop, hourly for first 48 h, then reduce as per response. Alternate regimen: Gatifloxacin 0.3% ophthalmic solution, 1 drop, hourly for 1st 48 h then reduce as per response | | | NCDC Guidelines[^2] |
|                  |                    | Intravitreal antibiotics (Injection vancomycin + Injection ceftazidime) | | | |
| Endophthalmitis (bacterial) | Post-ocular surgery: S.epidermidis, S. aureus, Streptococcus enterococci, Gram negative bacilli, Hematogenous: S.pneumoniae, N.meningitidis, S. aureus, Streptococcus, K. pneumoniae | Intravitreal antibiotics: Injection vancomycin + Injection ceftazidime + +Systemic antibiotics: Injection meropenem 1 gm IV q8h
Injection ceftriaxone 2 gm Ceftriaxone 2 gm IV q24h | Vitrectomy | | NCDC Guidelines[^2] |
the treatment of blepharitis. Macrolides (erythromycin and azithromycin) have the advantage of exhibiting anti-inflammatory and antibacterial properties, and are therefore ideal in blepharitis cases with co-existent bacterial infection and inflammation. In cases with significant ocular inflammation, topical anti-inflammatory agents (e.g., corticosteroids, cyclosporine) provide symptomatic relief. Thermal pulsation and intense pulsed light therapy are also used to treat posterior blepharitis due to meibomian gland dysfunction. Blepharitis has good prognosis; however it is sporadically associated with recurrent episodes due to the pathogenic susceptibility of the patient.

Conjunctivitis

Conjunctivitis or inflammation of the conjunctiva is the most common cause of acute red eye. Symptoms of conjunctivitis include intense redness of eyes, swelling of conjunctiva, watering of eyes,ropy discharge (pus or mucus), pain in the eyes, and sensitivity to light or blurred vision. Conjunctivitis can be infectious or non-infectious; viruses and bacteria are the most common infectious causes of conjunctivitis while non-infectious conjunctivitis is attributed to allergy, toxicity, and inflammation secondary to immune-mediated diseases. Common bacterial pathogens causing infectious conjunctivitis include S. aureus, S. pneumoniae, Haemophilus influenzae, Neisseria gonorrhoeae, and Chlamydia trachomatis. An observational study conducted in the ophthalmology OPD in a tertiary hospital in India reported infective conjunctivitis as the most commonly diagnosed ocular infection in 21.5% of patients. The primary cause of viral conjunctivitis is adenoviruses, herpes simplex virus, or varicella (herpes) zoster virus. Viral and bacterial conjunctivitis are highly contagious; therefore, patients are instructed to exercise proper eye and hand hygiene. It can be distinguished through symptomatic variability and slit lamp examination. Mild bacterial conjunctivitis is usually self-limiting; however, antibiotic treatment is necessary in severe cases characterized by purulent discharge, pain, and marked inflammation of the eyes. Fluoroquinolones (moxifloxacin, gatifloxacin and levofloxacin) are recommended for bacterial conjunctivitis as per the NCDC guidelines. Fluoroquinolones are recommended for wearers of contact lens, diagnosed with conjunctivitis to provide empiric coverage for Pseudomonas. Topical corticosteroids are not recommended for bacterial or viral conjunctivitis. Chlamydial infections, which include trachoma, neonatal inclusion conjunctivitis, and adult inclusion conjunctivitis are also common eye infections seen in India. Mass azithromycin treatment has been used for control of the disease, along with promotion of hygiene and environmental changes. Antimicrobial resistance in Chlamydia has thankfully remained low.

Dacryocystitis

Dacryocystitis is an infection of the nasolacrimal sac leading to inflammation and blockage of the nasolacrimal duct. Dacryocystitis manifests as epiphora, erythema, edema, induration, and pain over the nasolacrimal sac. Pathogenesis of dacryocystitis is the bacterial overgrowth in the lacrimal sac; common causative pathogens for dacryocystitis include strains of Staphylococcus and Streptococcus, Haemophilus influenza, P. aeruginosa and Fusobacterium. A prospective study from eastern India indicated that aerobic gram-positive isolates (74.2%) were the more frequently observed causative pathogens among 95 patients with unilateral chronic dacryocystitis, including a high prevalence of MRSA (>90%) in the S. aureus isolates. Acute dacryocystitis can be treated with topical antibiotic eye drops, oral antibiotics, and anti-inflammatory drugs. Broad-spectrum antibiotics and subsequent empiric treatments with fluoroquinolones (moxifloxacin, gatifloxacin, and ofloxacin), amoxicillin-clavulanic acid, and third generation cephalosporins represent the standard treatment pattern for infectious dacryocystitis. Intravenous antibiotics are recommended if dacryocystitis progresses to cellulitis despite oral antibiotic treatment. Warm compresses and crigler massages over the lacrimal sac are conservative treatments suggested along with antibiotics. Surgical interventions including syringing, probing, and external dacryocystorhinostomy (DCR) offer a definitive management for dacryocystitis. In a retrospective cohort study conducted over a period of 22 years among 320 patients with acute dacryocystitis presented in a tertiary eye care center in India, oral amoxicillin and dicoxacillin constituted 61% of the antibiotics chosen as initial medical management, while DCR was performed in 82.5% patients. In Mitra et al. study, highest sensitivity to linezolid (100%) and higher generation fluoroquinolones were observed among the gram-positive isolates.

Keratitis

Keratitis is an inflammation of the cornea characterized by the presence of white or yellowish infiltrates in the corneal stroma. Complications of keratitis include scarring in the cornea, and if left untreated, can lead to corneal opacity and blindness. A majority of keratitis cases in India are infectious due to bacterial, fungal, or viral pathogens. The most common bacterial pathogens of infectious keratitis are S. aureus, S. pneumoniae, S. pyogenes, Haemophilus and Pseudomonas species. Keratitis diagnosis is conducted through slit lamp examination while the corneal scraping for laboratory analysis helps to determine the causative organism. A specific diagnosis of the causative organism can assist in prompt and accurate therapy, and avoid redundant use of antibiotics. Topical broad-spectrum antibiotics, primarily fluoroquinolone monotherapy, have been the mainstay for the treatment of bacterial keratitis. According to the NCDC guidelines, topical moxifloxacin (0.5%) is recommended as the first line of treatment, and gatifloxacin (0.3%) as the alternative treatment for acute bacterial keratitis. Fortified antibiotics, cephalosporins (cefazolin 5% or cefuroxime 5%), and aminoglycosides (tobramycin 1.3%, gentamicin 1.4%) have been used topically in the treatment of bacterial keratitis. However, studies have shown similar efficacy with commercially available topical fluoroquinolone eye drops. They are useful in fluoroquinolone-resistant cases. Corticosteroids may be considered after 24 to 48 hours, as the causative pathogen is identified and primary therapy is effective. However, they should be avoided in viral and fungal keratitis. Surgical intervention may be required for severe infectious keratitis in the form of keratoplasty or amniotic membrane transplant. Recommending appropriate antimicrobial therapy also necessitates the knowledge of evolving local susceptibility patterns. A retrospective cross-sectional study spanning 12 years analyzing AMR trends.
in 3,685 bacterial keratitis isolates from a large tertiary eye care hospital in south India established that the two most common organisms presenting resistance were *S. pneumoniae* (33%) and *P. aeruginosa* (24%). A significant increase in MRSA isolates was observed during the 12-year study period together with increased fluoroquinolone resistance in *S. aureus* and MSSA isolates (e.g. cefoxitin resistance in MSSA increased from 11.1% in 2002 to 66.7% in 2013).[57]

Endophthalmitis

Endophthalmitis is a severe ocular inflammation triggered by infection of the intraocular tissues that can have potentially devastating vision consequences without prompt and effective treatment. A systematic review from India which included data from 1992 to 2012 reported that the incidence of clinical endophthalmitis ranged from 0.04% to 0.16%.[58] Endophthalmitis manifests itself as reduced or blurred vision, red eye, pain, and eyelid swelling. Progressive vitritis is a vital observation during diagnosis and ophthalmological examination in endophthalmitis.[3] Bacterial infections, mostly gram-positive Staphylococcus species (*S. epidermidis, S. aureus*), Streptococci, enterococci and gram-negative bacilli *Pseudomonas* species are the most common cause of postoperative endophthalmitis.[59,60]

Treatment for endophthalmitis must be prompt, even prior to a definitive diagnosis. Intravitreal antibiotic therapy is the main stay of treatment for endophthalmitis. First-line intravitreal antimicrobial agents for the management of endophthalmitis include glycopeptide (vancomycin), cephalexin (ceftazidime), and aminoglycoside (amicillin).[61] Alternative intravitreal antibiotics for potential use in management of endophthalmitis due to antimicrobial susceptibility to standard antimicrobials include oxazolidinone (linezolid), cyclic lipoglycopeptide (daptomycin), glycylcycline (tigecycline), carbapenem (imipenem), and fluoroquinolones (moxifloxacin, ciprofloxacin, levofloxacin).[59,62] Recommended systemic antibiotics for the treatment of endophthalmitis include meropenem (1 g, IV, every 8 hours), ceftiraxone (2 g, IV, every 2 hours) + vancomycin (1 g, IV, every 12 hours).[63] Vitrectomy with vitreous biopsy is recommended in severe endophthalmitis with vitritis and retinal infiltration. However, considerable antibiotic susceptibilities have also been observed globally in the spectrum of etiological agents of endophthalmitis.[64,65] In a study to determine the clinico-microbiological and antibiotic susceptibility profile in 1,110 patients diagnosed with endophthalmitis from a single center in India, gram-positive bacteria showed susceptibility to glycopeptides like vancomycin (80–100%) and fluoroquinolones (87–91%), whereas gram-negative bacteria (*Pseudomonas* and *Klebsiella*) showed susceptibility toward fluoroquinolones (61–82%).[66]

A recently published study estimated an increasing trend of antibiotic resistance of *Pseudomonas* to fluoroquinolones, amikacin, and ceftazidime in endophthalmitis, including alarming increase in multidrug resistance, particularly in post-surgical patients.[67] Despite aggressive treatment, prognosis in *Pseudomonas* endophthalmitis cases remains poor with a high number of cases requiring enucleation.[68]

Antimicrobial Resistance Trends in Ocular Infection

AMR has gained attention as a major global health threat of the 21st century owing to its current and potential consequences on public health, and economic burden.[69] AMR occurs when microorganisms develop cellular mechanism to adapt and transform on exposure to antibiotics, rendering the medication ineffective.[70] Being the world’s largest consumer of antibiotics for human health (10.7 units per person), India carries a major burden of AMR. AMR High rates of MRSA (ranging from 32–80%) have been reported in diverse studies.[71] An increase in MRSA from 29% of *S. aureus* isolates in 2009 to 39% in 2015 was observed in a large private laboratory network study.[72] The past decades have witnessed an alarming increase in AMR in general bacterial pathogens, and ocular pathogens are no exception.[9,12,13,60–69] The identification of causal pathogen for the ocular infection is crucial for treatment decision-making. However, to avoid treatment delays, preliminary selection of antibiotics for the treatment of ocular infections in clinical practice is empiric, and is based on the most frequently encountered pathogens, pharmacokinetics of the antibiotic, dosage, and costs.[43] Empirical treatment increases the probability of antibiotic prescription to a resistant pathogen that may subsequently lead to treatment failure. Variability and under-potency in generic ocular antibiotics could be potential contributors to emerging AMR.[70] A study on the unstable outcome of generic ciprofloxacin antibiotic eye drops in India, highlighted that about 20% of samples showed under-potency to the standard advisory ranges.[24] Antibiotic prescription pattern studies across ophthalmic OPDs in India identified antibiotic overuse, polypharmacy, and common prescription writing errors such as undefined duration of therapy, frequency of administration, or dosage form.[71,72] A recent study to analyze antibiotic prescription patterns in an ophthalmology OPD in a tertiary care hospital in India reported only 1.6% of the prescriptions from the National Essential Medicines List (2015).[73] Prescribing peri-operative antibiotic regimen is a common practice among ophthalmologists,[74] however, judicious and optimal use of antibiotics should be considered to control the threat of AMR.[79] Widespread antibiotic susceptibilities have been observed among common ocular antibiotics in multi-center AMR surveillance studies conducted in the past decade. The Surveillance Network (TSN) data on ocular isolates of *S. aureus* (2000–2005) conducted in the US estimated that the proportion of ocular infections caused by MRSA increased from 29.5% in 2000 to 41.6% in 2005.[65] Another surveillance study was ocular tracking resistance in the U.S. Today (Ocular TRUST) conducted in 2005–2006.[62] Ocular TRUST evaluated the in-vitro antimicrobial susceptibility of *S. aureus, S. pneumoniae, and H. influenzae* to a variety of commonly used ophthalmic antibiotics including fluoroquinolones, aminoglycosides, penicillin, macrolides, polymyxin B, and trimethoprim.[75] Ocular TRUST study reported virtually identical MSSA (79.9% to 81.1%) or MRSA (15.2%) susceptibility patterns for fluoroquinolone.[76] Most recent ophthalmic surveillance study from the US setting is the AMR monitoring in ocular microorganisms (ARMOR) conducted in 2009. The study prospectively evaluated antimicrobial susceptibility of *S. aureus, S. pneumoniae, H. influenzae, and P. aeruginosa* isolated from cases of ocular infections. Thirty-four institutions across the US participated in the ARMOR study, which demonstrated a reduction of MRSA as compared to TSN study data (39% vs 41.6%, respectively).[71]

Although there is a dearth of largescale surveillance studies determining antibiotic susceptibility patterns
Across India, few local epidemiological studies have added evidence for ocular antibiotic susceptibilities. A 5-year retrospective analysis of microbiological samples from patients diagnosed with ocular infections demonstrated susceptibility to moxifloxacin (98.7%) and vancomycin (97.9%) among gram-positive isolates, and to amikacin (93.5%) and gatifloxacin (92.7%) among gram-negative isolates. Recent years have witnessed an increasing trend in AMR across India. A cross-sectional study from South India in patients with bacterial keratitis, underlined increased ofloxacin resistance in MSSA from 11.1% in 2002 to 66.7% in 2013. Another retrospective review conducted in a tertiary care center in India to analyze the evolving trends of MRSA ocular infections revealed an increase in MRSA-associated ocular infections from 26% in 2006 to 38% in 2008. Further long-term antibiotic resistance surveillance studies are justified to formulate rationale-based decisions in antibiotic treatment of bacterial ocular infections in India.

Antimicrobial Stewardship Programs

Antimicrobial stewardship (AMS) refers to a coherent set of actions at the individual, national, or global level to promote appropriate use of antibiotics through implementation of evidence-based interventions. A global action plan was adopted by the World Health Organization (WHO) in 2015 to combat AMR. Strategic objectives of this action plan include enhancing awareness and understanding of AMR, strengthening knowledge through surveillance and research, and optimizing the use of antibiotics. With AMR emerging as a global health threat, the perspective of AMS has broadened, mirroring its application in diverse range of contexts from hospitals, One Health AMS programs, and the WHO global stewardship framework. AMS programs have effectively reduced the emergence of AMR and healthcare-associated infections, use of targeted antimicrobials, and duration of antibiotic therapy. It has also contributed to a reduction in healthcare-related costs. A systematic review to determine the effect of AMS programs involving 77 studies showed reduced antibiotic use, and associated costs in 90% and 100% studies respectively.

The effect of antibiotic resistance must be reduced through largescale implementation of surveillance activities and training of health professionals. Ophthalmologists must invariably comply with the antibiotic prescription guidelines. The concentration of antibiotics must be more than or equal to the minimum inhibitory concentration, and preferably the minimum bactericidal concentration at the site of infection. Combination therapy can be considered in empiric treatment to enhance therapeutic efficacy or by broadening the spectrum of activity. Irrational use of antibiotics such as overuse, polypharmacy or undefined duration of therapy, frequency of administration or dosage form must not be exercised.

Phase IV studies, or post-marketing surveillance of antibiotic drugs hold the key to analyzing real-world usage patterns of the drugs as well as its abuse and overuse. These studies need to be conducted from time to time, analysed, and prescription guidelines issued in order to ensure homogeneity of prescriptions throughout the country.

The Indian Ministry of Health & Family Welfare also formulated the National Action Plan for AMR (NAP-AMR) containment in April 2017. The strategic priorities of NAP-AMR are to a) strengthen awareness and understanding of AMR through effective communication, education, and training; b) enhance knowledge and evidence in AMR through surveillance; c) reduce the incidence of infection through effective infection prevention and control; d) optimize the use of antimicrobial agents in all sectors; e) promote investments for AMR activities, research and innovations; and f) strengthen India’s leadership on AMR by establishing collaborations on AMR at the international, national and sub-national levels. Though AMR in ocular pathogens have evolved with the widespread use of antimicrobials, AMS strategies in ophthalmology have not been explored at the global or national level. There is sparse literature globally that highlights this pressing issue in ophthalmology. This is an elementary article in India that underlines the prominence of AMR in ocular infections, and emphasizes the establishment of national ocular AMS programs that will aid in the rational use of antimicrobials in this field. General measures from the NAP-AMR program can also be adopted in ophthalmology practice. Limiting indiscriminate use of antibiotics for ophthalmic use and choosing wisely can reduce AMR. Furthermore, largescale microbiological surveillance and antibiotic susceptibility studies for ocular infections in India are indispensable.

Summary and Recommendations

With the increase in AMR of ocular infections in India, there is a compelling need to establish antimicrobial prescription guidelines and policies for ophthalmic infections. Largescale AMR surveillance studies across India are a requisite to reassess the ophthalmic antimicrobial prescription policies in India in accordance with local resistance patterns. Evidence from these surveillance studies will assist in tailoring antibiotic prescription policies by patient demographics and clinical settings. Emergence of antibiotics embarked a golden era in healthcare, and enabled humanity to overcome its worst nemesis—the microbes. It is ethically imperative that rational and judicious use of antibiotics is exercised, to preserve the efficacy of these magic drugs for continued use.

Based on experiences with antimicrobial stewardship in other therapy areas, it is recommended that a similar programme be initiated in the field of ophthalmology with a focus on the following:

1. Research to identify the current use of antimicrobials in ophthalmology. Regular reporting of information on antibiotic use and resistance to prescribers, pharmacists, nurses, and hospital leadership.
2. Collaboration with microbiologists/laboratories to understand current sensitivity and resistance patterns in India.
3. Nodal society/organization in the field of ophthalmology can lead the creation of guidelines/protocols for antimicrobial usage for the management of ocular infections.
4. Educate prescribers, pharmacists, nurses, and patients about adverse reactions to antibiotics, antibiotic resistance, and optimal prescription for ocular infections.
5. Regular monitoring and assessment to evaluate the
implementation of the guidelines and the impact of interventions in preventing antimicrobial resistance.

Acknowledgments

The authors would like to thank Vibha Dhamija and Smitha Sreedharan from IQVIA for their medical writing and editing support.

Author declaration

All authors adhered to the ICMJE authorship criteria. All authors reviewed and revised the manuscript for important intellectual content.

Ethics approval

No ethical approval was required as the information herein involves no use of clinical or human data.

Financial support and sponsorship

This study was funded by Novartis Healthcare Private Limited.

Conflicts of interest

Dr Neha Gurha and Dr Nitin Maksane are employees of Novartis Healthcare Private Limited. The other authors have no conflicts of interest to declare.

References

1. Donahue SP, Khoury JM, Kowalski RP. Common ocular infections. A prescriber’s guide. Drugs 1996;52:526-40.
2. Jackson WB. Blepharitis: Current strategies for diagnosis and management. Can J Ophthalmol 2008;43:170-9.
3. Kernt M, Kampik A. Endophthalmitis: Pathogenesis, clinical presentation, management, and perspectives. Clin Ophthalmol 2010;4:121-35.
4. Weng T-H, Chang H-C, Chung C-H, Lin F-H, Tai M-C, Tsao C-H, et al. Epidemiology and mortality-related prognostic factors in endophthalmitis. Invest Ophthalmol Vis Sci 2018;59:2487-94.
5. Alfonso SA, Fawley JD, Alexa Lu X. Conjunctivitis. Prim Care 2015;42:325-45.
6. Teweldemedhin M, Gebreyesus H, AtsbaHAH, Asgedom SW, Saravanaan M. Bacterial profile of ocular infections: A systematic review. BMC Ophthalmol 2017;17:212.
7. Snyder RW, Glasser DB. Antibiotic therapy for ocular infection. West J Med 1994;161:579-84.
8. Bertino JS Jr. Impact of antibiotic resistance in the management of infectious complications: The role of current and future antibiotics. Clin Ophthalmol 2009;3:507-21.
9. Sharma S. Antibiotic resistance in ocular bacterial pathogens. Indian J Med Microbiol 2011;29:218-22.
10. Fintelmann RE, Hoskins EN, Lietman TM, Keenan JD, Gaynor BD, Cevallos V, et al. Topical fluoroquinolone use as a risk factor for in vitro fluoroquinolone resistance in ocular cultures. Arch Ophthalmol (Chicago, Ill: 1960) 2011;129:399-402.
11. Garg P, Roy A. Update on antimicrobial resistance and ocular isolates. Curr Ophthalmol Rep 2013;3:169-74.
12. Asbell PA, Colby KA, Deng S, McDonnell P, Meisler DM, Raizman MB, et al. Ocular TRUST: Nationwide antimicrobial susceptibility patterns in ocular isolates. Am J Ophthalmol 2008;145:951-8.
13. Ahmad S, Ahmad S, Qais FA, Khan MS, Ahmad I. Emergence and Spread of Multidrug Resistance in Ocular Bacterial Pathogens: A Current Update. In: Ahmad I, Ahmad S, Rumbaugh K. (eds) Antibacterial Drug Discovery to Combat MDR. Springer, Singapore. 2019. https://doi.org/10.1007/978-981-13-9871-1_3
14. Vola ME, Moriyama AS, Lisboa R, Vola MM, Hirai FE, Bispo PJ, et al. Prevalence and antibiotic susceptibility of methicillin-resistant Staphylococcus aureus in ocular infections. Arq Bras Oftalmol 2013;76:350-3.
15. Hassoun A, Linden PK, Friedman B. Incidence, prevalence, and management of MRSA bacteremia across patient populations—a review of recent developments in MRSA management and treatment. Crit Care 2017;21:211. doi: 10.1186/s13054-017-1801-3.
16. Jonas OB I, Alec, Berthe, Franck Cesar Jean, Le Gall, Francois G., World Bank Group; Drug-resistant Infections: A threat to our economic future (Vol. 2): Final report (English), Washington, DC 2017. Available from: http://documents1.worldbank.org/curated/en/32331493996993758/pdf/-final-report.
17. ICMR. Treatment Guidelines for Antimicrobial Use in Common Syndromes 2019. Available from: https://main.icmr.nic.in/sites/default/files/guidelines/Treatment_Guidelines_2019_Final.pdf.
18. Ranjit K, Sharma S, Shivaji S. Microbes of the human eye: Microbiome, antimicrobial resistance and biofilm formation. Exp Eye Res 2021;205:108476. doi: 10.1016/j.exer.2021.108476.
19. Al-Mujaini A, Al-Kharusi N, Thakral A, Wali UK. Bacterial keratitis: Perspective on epidemiology, clinico-pathogenesis, diagnosis and treatment. Sultan Qaboos Univ Med J 2009;9:184-95.
20. Sharma S. Ocular infections: Research in India. India J Med Microbiol 2010;28:91-4.
21. Hina K, Chopra D, Shoma M, Pooja M. Pharmacoepidemiological observational study of antimicrobial use in outpatients of ophthalmology department in North Indian population. J Pharm Bioallied Sci 2018;10:72-6.
22. Banerjee I, Bhandury T, Sengupta T, Roy D. Drug utilization study in ophthalmology out-patient department of a Medical College in India. Ann Med Health Sci Res 2014;4:667-70.
23. Nithya V, Rathinam S, Siva Ganesa Karthikeyan R, Lalitha P. A ten year study of prevalence, antimicrobial susceptibility pattern, and genotypic characterization of Methicillin resistant Staphylococcus aureus causing ocular infections in a tertiary eye care hospital in South India. Infect Genet Evol 2019;69:203-10.
24. Weir RE, Zaidi FH, Charters DG, Bunce C, Soltani M. Variability in the content of Indian generic ciprofloxacin eye drops. Br J Ophthalmol 2005;89:1094-6.
25. Finch R. Generic antibiotics, antibiotic resistance, and drug licensing. Lancet Infect Dis 2010;10:754.
26. Kefalidis T, Falagas ME. Substandard/counterfeit antimicrobial drugs. Clin Microbiol Rev 2015;28:443-64.
27. WHO. World Health Organization, Antimicrobial Stewardship Programmes in Healthcare Facilities in low and Middle-Income Countries Geneva 2019. Available from: https://apps.who.int/iirs/bitstream/handle/10665/329404/9789241515481-eng.pdf.
28. Doron S, Davidson LE. Antimicrobial stewardship. Mayo Clin Proc 2011;86:1113-23.
29. NCDC. National Centre for Disease Control, National Programme on AMR Containment, Ministry of Health & Family Welfare, Government of India 2020. Available from: https://ncdc.gov.in/index.php?lang=1&level=2&sublinkid=384&lid=344.
30. Watson S, Cabrera-Aguas M, Khoo P. Common eye infections. Aust Prescr 2018;41:67-72.
31. Toyos R, McGill W, Briscoe D. Intense pulsed light treatment for dry eye disease due to meibomian gland dysfunction; a 3-year retrospective study. Photomed Laser Surg 2015;33:41-6.
32. NCDC. National Treatment Guidelines for Antimicrobial Use in Infectious Diseases, National Centre for Disease Control, Directorate General of Health Services Ministry of Health & Family Welfare, Government of India 2016. Available from: https://ncdc.gov.in/WriteReadData/8892aFile22.pdf.
33. Pinar‑Sueiro S, Sota M, Lerchundi T-X, Gibelalde A, Berasategui B,
Vilar B, et al. Dacryocystitis: Systematic approach to diagnosis and therapy. Curr Infect Dis Rep 2012;14:137-46.

34. Goldstein T, Barmettler A, Vargason CW, Burkat CN, Goel S. American Academy of Ophthalmology. Dacryocystitis 2020. Available from: https://www.eyewiki.org/Dacryocystitis.

35. MoHFW. National Institute of Health and Family Welfare, Ministry of Health and Family Welfare (MoHFW), Government of India, Dacryocystitis Available from: https://www.nhp.gov.in/disease/eye-ear/dacryocystitis.

36. Tuli S, Gray M. Surgical management of corneal infections. Curr Opin Ophthalmol 2016;27:340-7.

37. NHP. National Health Portal India, Ministry of Health and Family Welfare (MoHFW), Government of India, Blepharitis 2016. Available from: https://www.nhp.gov.in/disease/eye-ophthalmology-blepharitis.

38. Eberhardt M, Rammohan G. Blepharitis. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2019. Available from: https://www.ncbi.nlm.nih.gov/books/NBK459305/.

39. Pflugfelder SC, Karpecki PM, Perez VL. Treatment of blepharitis: Recent clinical trials. Ocular Surface 2014;12:273-84.

40. Duncan K, Jeng BH. Medical management of blepharitis. Curr Opin Ophthalmol 2015;26:289-94.

41. AAO. American Academy of Ophthalmology Preferred Practice Pattern Cornea/External Disease Committee; Blepharitis PPP-2018 2018. Available from: https://www.aaao.org/preferred-practice-pattern/blepharitis-ppp-2018.

42. Ryder EC, Benson S. Conjunctivitis. [Updated 2021 Aug 11]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls. Available from: https://www.ncbi.nlm.nih.gov/books/NBK541034/.

43. Varu DM, Rhee MK, Akpek EK, Amescua G, Farid M, Garcia-Ferrer FJ, et al. Conjunctivitis preferred practice pattern®. Ophthalmology 2019;126:P94‑169.

44. Satpathy G, Behera HS, Ahmed NH. Chlamydia eye infections: Current perspectives. Indian J Ophthalmol 2017;65:97-102.

45. Taylor RS, Ashurst JV. Dacryocystitis. 2020 In: StatPearls [Internet]. Treasure Island (FL): StatPearls. Available from: https://www.ncbi.nlm.nih.gov/books/NBK470565/.

46. Pornpanich K, Luemsamran P, Leelaporn A, Santisuk J, Tesavibul N, Lertsuwonroj B, et al. Microbiology of primary acquired nasolacrimal duct obstruction: Simple epithela, acute dacryocystitis, and chronic dacryocystitis. Clin Ophthalmol 2016;10:337-42.

47. Mitra S, Chayani N, Mohapatra D, Barik MR, Sharma S, Basu S. High prevalence of Biofilm-forming MRSA in the conjunctival flora in chronic dacryocystitis. Semin Ophthalmol 2019;34:74-9.

48. Ali MJ, Joshi SD, Naik MN, Honavar SG. Clinical profile and management outcome of acute dacryocystitis: Two decades of experience in a tertiary eye care center. Semin Ophthalmol 2015;30:118-23.

49. Gupta N, Tandon R, Gupta SK, Sreenivas V, Vashist P. Burden of corneal blindness in India. Indian J Community Med 2013;38:198-206.

50. Acharya M, Farooqui JH, Gaba T, Gandhi A, Mathur U. Delhi infectious keratitis study: Update on clinic microbiological profile and outcomes of infectious keratitis. J Curr Ophthalmol 2020;32:249-55.

51. Lalitha P, Prajna NV, Manoharan G, Srinivasan M, Mascarenhas J, Das M, et al. Trends in bacterial and fungal keratitis in South India, 2002-2012. Br J Ophthalmol 2015;99:192-4.

52. Mohod P, Nikose A, Laddha P, Bhati S. Incidence of various causes of infectious keratitis in the part of rural central India and its visual morbidity: Prospective hospital-based observational study. J Clin Ophthalmol Res 2019;7:31-4.

53. American Academy of Ophthalmology. Bacterial Keratitis Preferred Practice Pattern. San Francisco, CA: American Academy of Ophthalmology; 2018. Available from: https://www.aaojournal.org/article/S0161-6420 (18) 32644-7/pdf. [Last accessed on 2020 Sep 22].

54. Ezisi CN, Okoye O, Ezeanosike E, Ginger-Eke H, Arinze OC. Microbial keratitis—A review of epidemiology, pathogenesis, ocular manifestations, and management. Niger J Ophthalmol 2018;26. doi: 10.4103/nijo.nijo_2_18.

55. Hanet MS, Jamart J, Chaves AP. Fluoroquinolones or fortified antibiotics for treating bacterial keratitis: Systematic review and meta-analysis of comparative studies. Can J Ophthalmol 2012;47:493-9.

56. Dikmetag Ö, Deniz Y, Kocabeyoğlu S, Başol M, İrkeç M. The value of fortified aminoglycoside/cephalosporin treatment as first-line treatment and in fluoroquinolone-resistant bacterial keratitis. Turk J Ophthalmol 2020;50:258-63.

57. Lalitha P, Manoharan G, Karpagam R, Prajna NV, Srinivasan M, Mascarenhas J, et al. Trends in antibiotic resistance in bacterial keratitis isolates from South India. Br J Ophthalmol 2017;101:108.

58. Sheu SJ. Endophthalmitis. Korean J Ophthalmol 2017;31:283-9.

59. Lalitha P, Sengupta S, Ravindran R, Sharma S, Joseph J, Ambiya V, et al. A literature review and update on the incidence and microbiology spectrum of postcataract surgery endophthalmitis over past two decades in India. 2017;65:673-7.

60. Birnbaum F Gupta G. Endogenous Endophthalmitis: Diagnosis and Treatment. American Academy of Ophthalmology; 2020. Available from: https://www.aao.org/eyenet/article/endogenous-endophthalmitis-diagnosis-treatment.

61. Satpathy G, Nayak N, Wadhwani M, Venkatesh P, Kumar A, Sharma Y, et al. Clinico microbiological profile of endophthalmitis: A 10 year experience in a tertiary care center in North India. 2017;60:214-20.

62. Relhan N, Pathengay A, Schwartz SG, Flynn HW Jr. Emerging worldwide antimicrobial resistance, antibiotic stewardship and alternative intravitreal agents for the treatment of endophthalmitis. Retina (Philadelphia, Pa) 2017;37:811-8.

63. Pan U, Jain A, Gabert J, Kumar B, Sindal M. Antibiotic sensitivity trends of pseudomonas endophthalmitis in a tertiary eye care center in South India: A 12-year retrospective study. Indian J Ophthalmol 2020;68:627-31.

64. Sridhar J, Kuriyan AE, Flynn HW Jr, Miller D. Endophthalmitis caused by pseudomonas aeruginosa: Clinical features, antibiotic susceptibilities, and treatment outcomes. Retina (Philadelphia, Pa) 2015;35:1101-6.

65. World Health Organization. Antimicrobial Resistance-Global Report on Surveillance. Geneva: WHO; 2014. Available from: https://www.who.int/drugresistance/documents/surveillancereport/en/.

66. CDC. Centers for Disease Control and Prevention, Antibiotic/ Antimicrobial Resistance (AR/AMR) Atlanta 2020. Available from: https://www.cdc.gov/drugresistance/about.html.

67. Van Boechel TP, Gandra S, Ashok A, Caudron Q, Grenfell BT, Levin SA, et al. Global antibiotic consumption 2000 to 2010: An analysis of national pharmaceutical sales data. Lancet Infect Dis 2014;14:742-50.

68. CDDEP. Center for Disease Dynamics, Economics & Policy, Resistance Map, India, Antibiotic resistance of Staphylococcus aureus in India 2020. Available from: https://resistancemap.cddep.org/CountryPage.php?countryId=17&country=India.

69. Chang VS, Dhaliwal DK, Raju L, Kowalski RP. Antibiotic resistance in the treatment of Staphylococcus aureus keratitis: A 20-year review. Cornea 2015;34:698-703.

70. Venkatesh M, Bairagi VG, Sasikumar KC. Generic antibiotic industries: Challenges and implied strategies with regulatory
perspectives. J Pharm Bioallied Sci 2011;3:101-8.

71. Patel DR, Patel PP, Bhagat PR, Gandhi AM, Desai MK. An analysis of the use of antimicrobial agents in outdoor patients of ophthalmology. J Family Med Prim Care 2019;8:2676-80.

72. NHP. National Health Portal of India National List of Essential Medicines (NLEM) 2015. Available from: https://www.nhp.gov.in/NHPFiles/NLEM%2C%202015.pdf. [Last accessed on 2020 Sep 22].

73. Jain AK, Naimi S, Jain S. Assessment of antimicrobial prescribing pattern in the outpatient department of ophthalmology in a tertiary care hospital of Western Uttar Pradesh, India. Nepal J Ophthalmol 2018;10:130-8.

74. Goray A, Arora S, Yadava D, Gupta S, Ghosh B. A review of antibiotic prophylaxis for post-operative endophthalmitis. Delhi J Ophthalmol 2016;26:163-9.

75. Barry P, Cordovés L, Gardner S. ESCRs Guidelines for Prevention and Treatment of Endophthalmitis Following Cataract Surgery: Data, Dilemmas and Conclusions. Dublin, Ireland: European Society of Cataract and Refractive Surgeons; 2013. Available from: https://www.escrs.org/downloads/Endophthalmitis -Guidelines.pdf.

76. Asbell PA, Sahm DF, Shaw M, Draghi DC, Brown NP. Increasing prevalence of methicillin resistance in serious ocular infections caused by *staphylococcus aureus* in the United States: 2000 to 2005. J Cataract Refract Surg 2008;34:814-8.

77. Bharathi M, Ramakrishnan R, Shivakumar C, Meenakshi R, Lionalraj D. Etiology and antibacterial susceptibility pattern of community-acquired bacterial ocular infections in a tertiary eye care hospital in south India. India J Ophthalmol 2010;58:497-507.

78. Bagga B, Reddy AK, Garg P. Decreased susceptibility to quinolones in methicillin-resistant *staphylococcus aureus* isolated from ocular infections at a tertiary eye care centre. Br J Ophthalmol 2010;94:1407-8.

79. Gerding DN. The search for good antimicrobial stewardship. Jt Comm J Qual Improv 2001;27:403-4.

80. WHO. World Health Organization; Global action plan on antimicrobial resistance 2015. Available from: https://www.who.int/antimicrobial-resistance/publications/global-action-plan/en/.

81. Powell N, Davidson L, Yelling P, Collinson A, Pollard A, Johnson L, *et al*. Developing a local antimicrobial resistance action plan: The Cornwall one health antimicrobial resistance group. J Antimicrob Chemother 2017;72:2661-5.

82. WHO. Global Framework for Development & Stewardship to Combat Antimicrobial Resistance. Switzerland: World Health Organization; 2018 Available from: https://www.who.int/phi/news/WHO_OIE_FAO_UNEP_WorKpaper_of_theFramework_FINAL.pdf?ua=1. [Last accessed on 2020 Sep 22].

83. Al-Omari A, Al Mutair A, Alhumaid S, Salih S, Alanazi A, Albarsan H, *et al*. The impact of antimicrobial stewardship program implementation at four tertiary private hospitals: Results of a five-years pre-post analysis. Antimicrob Resist Infect Control 2020;9:95.

84. Garcia-Rodriguez JF, Bardán-García B, Peña-Rodriguez MF, Álvarez-Díaz H, Mariño-Callejo A. Meropenem antimicrobial stewardship program: Clinical, economic, and antibiotic resistance impact. Eur J Clin Microbiol Infect Dis 2019;38:844-51.

85. Lee CF, Cowling BJ, Feng S, Aso H, Wu P, Fukuda K, *et al*. Impact of antibiotic stewardship programmes in Asia: A systematic review and meta-analysis. J Antimicrob Chemother 2018;73:844-51.

86. Maharana P, Chhablani J, Das T, Kumar A, Sharma N. All India Ophthalmological Society members survey results: Cataract surgery antibiotic prophylaxis current practice pattern 2017. India J Ophthalmol 2018;66:820-4.

87. Bremond-Gignac D, Chiambaretta F, Milazzo S. A European perspective on topical ophthalmic antibiotics: Current and evolving options. Ophthalmol Eye Dis 2011;3:29-43.

88. Smith PG, Morrow RH, Ross DA, editors. Field Trials of Health Interventions: A Toolbox. 3rd ed. Oxford (UK): OUP Oxford; 2015 Jun 1. PMID: 26225404.

89. NHP. National Health Program, Ministry of Health & Family Welfare-Government of India. National action plan on AMR (NAP-AMR) 2017. Available from: https://ncdc.gov.in/WriteReadData/linkimages/AMR/File645.pdf.

90. Grosso A, Ceruti P, Scarpa G, Giardini F, Marchini G, Aragona E, *et al*. Choosing wisely and the use of antibiotics in ophthalmic surgery: There is more than meets the eye. Eur J Ophthalmol 2018;28:625-32.